Psilocybin not checked
COMPASS Pathways · COMP360
FollowEvery change as it happens, and a Monday email
Trials
6 active
11 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Treatment Resistant Depression, PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder
- Main trialPhase 3
- “Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)”In the company’s words, NCT05711940 on ClinicalTrials.gov
- Other names
- COMP360
Other drugs for Treatment Resistant Depression
- NRX-101NeuroRx, Inc. · Phase 2/3
- EsketamineJohnson & Johnson (Janssen) · Phase 3
- BPL-003Beckley Psytech Limited · Phase 2
- ACP-211ACADIA Pharmaceuticals Inc. · Phase 2
- ALTO-207Alto Neuroscience · Phase 2
Coming up1
- Nov 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 13 Nov 2025 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | |
| Phase 2/3Recruiting | Nov 2028 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | |
| Phase 2Active, not recruiting | Sep 2025 | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | |
| Phase 3Completed | 28 May 2025 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | |
| Phase 2Completed | 30 Jul 2021 | The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | |
| Phase 2Completed | 14 Oct 2021 | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | |
| Phase 2Completed | 12 Feb 2024 | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | |
| Phase 2Completed | 18 Nov 2024 | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | |
| Phase 2Authorised | not given | The impact of psilocybin on pain in fibromyalgia patients: a multicenter trial | |
| Phase 2Authorised | not given | Regression of Atherosclerosis induced by liFe chAnging Experience with psiLocybin | |
| Phase 2Authorised | not given | Psilocybin in treatment-resistant depression |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026